Olodanrigan (EMA401)

Olodanrigan (EMA401) is an antagonist of Angiotensin Receptors and PD-1 / PD-L1 used in studies of MAPK / ERK Signaling and Immune Signaling and related signaling programs. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses in cancer, cardiovascular, and immunology models.

By blocking Angiotensin Receptors and PD-1 / PD-L1, Olodanrigan (EMA401) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses. The gpcr annotation adds relevance to GPCR pharmacology, ligand-binding, and signaling assays, together with downstream-response mapping in the same experimental setting. In cancer, cardiovascular, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Angiotensin Receptors and PD-1 / PD-L1
• Pathway perturbation studies connected to MAPK / ERK Signaling and Immune Signaling and related signaling programs
• Receptor-blockade and ligand-competition studies
• GPCR pharmacology, ligand-binding, and signaling assays

Overall, Olodanrigan (EMA401) is appropriate when a defined chemical perturbant is needed to connect Angiotensin Receptors and PD-1 / PD-L1 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cardiovascular, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.